Rabu, 21 Agustus 2019

Germany for First Time Sells 30-Year Bonds Offering Negative Yields - The Wall Street Journal

Germany sold 30-year debt at a negative yield for the first time, as investors desperate for safe assets bet that further falls in yields will boost the value of the bonds in the future.

Investors buying debt at a negative yield get back less than they paid if they hold on until maturity. In Wednesday’s sale, Germany borrowed €824 million ($914 million) through bonds that pay no interest. The bonds were sold slightly above face value, so when they mature in 2050, Germany will pay back €795 million.

Demand for government debt and high-grade corporate bonds has been huge this year, after major central banks responded to growing fears of a global slowdown with fresh rounds of interest-rate cuts or other looser monetary policy.

The European Central Bank is a big buyer of German government bonds, while other demand for negative-yielding debt comes from asset managers and investors who use such bonds as hedges for other parts of their portfolios or as part of derivatives-based swaps trades.

One way investors could make money is if rates continue to drop. Bond prices rise as yields fall.

“Why are people buying at negative yields? It is mainly in expectation that you’re going to be able to sell to someone at a higher price later on,” said Andrea Iannelli, investment director, fixed income at Fidelity International. “Whatever the yield you have to assume you’re going to make more on the capital gain than lose on the yield.”

The bond sale caught the attention of President Trump, who tweeted Wednesday that it underscores his point that U.S. interest rates should be lower. “So Germany is paying Zero interest and is actually being paid to borrow money, while the U.S., a far stronger and more important credit, is paying interest,” he tweeted.

The German sale adds to the roughly $16 trillion of negative-yielding bonds outstanding world-wide, many of which are from European governments or are state-sponsored agency bonds. Only about 20% of these were actually sold with a negative yield at issue, while the rest have seen yields fall in secondary trading.

Up to €2 billion of Germany’s new 30-year bonds were offered for sale Wednesday, but the auction drew €869 million of bids. The remaining bonds were retained by the Bundesbank and will be sold into the market over time.

Investors who bid were still willing to pay more than face value to buy €824 million worth of the debt, which pushed the overall yield on the bond into negative territory, at minus 0.11%. By late afternoon, the yield had declined to minus 0.153%, according to Tradeweb.

“Even if the auction wasn’t fully subscribed I wouldn’t say it’s a bad result for Germany,” said Alberto Gallo, head of macro strategies at fund manager Algebris.

Germany has been selling shorter-dated debt with negative yields since the ECB pushed its benchmark policy rate negative in 2014. But this is the first time long-dated bonds, often owned by pension funds and insurance companies that have liabilities spread out over decades, have sold with the promise of returning less than investors put in.

Because yields on shorter-maturity German debt are so low—two-year debt yielded minus 0.91% Wednesday—demand for longer-dated bonds or even hoarding physical cash could pick up.

“If [short-dated] yields fall much further into negative territory, investors looking for safe assets will opt for cash in the vault,” said Christian Kopf, head of fixed income at German fund manager Union Investment. “Yields on 30-year bunds may have further to fall as the market prices in a very long period of negative central bank deposit rates.”

When Germany last sold long-term bonds in July, investors bought them at a positive yield of 0.3%. The yield on these bonds, which mature in 2048, was minus 0.182% by Wednesday afternoon.

Another factor driving investors into negative-yielding bonds: asset managers who are more interested in relative performance, said Piers Ronan, a debt-capital markets banker at Credit Suisse. “If they hold funds in cash instead it might cost them more,” he said, since banks in Europe charge large depositors to hold money in savings.

Since the start of 2016, more than $3 trillion of bonds has been sold with a negative yield at issue, according to data from Barclays . While these were mostly government and agency debt, they also included more than $11 billion of corporate bonds, from companies such as French drugmaker Sanofi SA and German consumer goods group Henkel AG & Co.

German Chancellor Angela Merkel, whose government sold 30-year bonds at a negative yield for the first time. Photo: halldor kolbeins/Agence France-Presse/Getty Images

U.S.-based Philip Morris International Inc. sold €500 million of seven-year bonds at a yield of minus 0.18% at the end of July, according to Barclays data.

The proliferation of negative-yield debt around the world has helped pull down U.S. Treasury yields, which look substantial by comparison even as they sit near historic lows.

The yield on the benchmark 10-year U.S. Treasury note settled Wednesday at 1.577%, compared with 1.557% Tuesday. The yield on the 30-year bond closed at 2.051%, having rebounded modestly after dropping to a record low last week.

Corrections & Amplifications
Investors bought €824 million of debt, meaning the German government will pay back €795 million in 30 years’ time. An earlier version of this article incorrectly stated that investors bought €869 million of debt, meaning the government will repay €839 million. (Aug. 21, 2019)

Write to Paul J. Davies at paul.davies@wsj.com and Patricia Kowsmann at patricia.kowsmann@wsj.com

Copyright ©2019 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Let's block ads! (Why?)


https://www.wsj.com/articles/germany-for-first-time-sells-30-year-bonds-offering-negative-yields-11566385847

2019-08-21 19:41:00Z
CAIiEJNGMQjvFEgU-ihQYXTwDOEqGAgEKg8IACoHCAow1tzJATDnyxUwiqe0AQ

Retirement account millionaires rise at Fidelity - Fox Business

The number of people with 401(k) and IRA balances that topped a million dollars hit a record in the second quarter.

Continue Reading Below

The number of investors with at least $1 million in their 401(k) accounts at Fidelity reached 196,000, according to USA Today.

That is up from the 180,000 in the previous quarter.

IRA millionaires increased to 179,700 from 168,100.

Investors recouped the money that they lost toward the end of 2018.

The average account balances also increase for 401(k) and IRAs by 2 percent and 3 percent respectively.

MORE FROM FOXBUSINESS.COM...

Helping the accounts were the gains in the stock market which included a 2.6 percent rise in the Dow Industrials and a 3.8 percent increase in the S&P 500.

The report said that another factor helping to boost balances was the fact that employers were automatically enrolling new employees into company retirement plans.

CLICK HERE TO READ MORE ON FOX BUSINESS

Employers are also increasing the default contribution rate at 6 percent or higher, although most companies set it around 3 percent.

Workers are also contributing more to their accounts.

Let's block ads! (Why?)


https://www.foxbusiness.com/personal-finance/retirement-account-millionaires-rise-at-fidelity

2019-08-21 10:12:24Z
52780359469485

Selasa, 20 Agustus 2019

On Apple Card launch day, Mastercard touts security, Goldman says it’s only the beginning - 9to5Mac

After gradually rolling out to testers over the last two weeks, Apple Card today officially launched to everyone. In conjunction with that launch, both Mastercard and Goldman Sachs are touting their newfound partnership with Apple.

Sylvania HomeKit Light Strip

First off, Mastercard’s president of North American operations Craig Vosburg took to CNBC today to detail the security behind Apple Card. Vosburg explained that while not having a card number on the physical helps with security, even bigger security measures are being taken behind the scenes.

Vosburg said that Mastercard is scrambling the 16-digit card number in a way that only it and Goldman Sachs can recognize. If the card number appears somewhere it shouldn’t, they can instantly kill it:

We’re taking the digital representation of that 16-digit number and scrambling [it] into a code that only we and Goldman Sachs can recognize. We know where it’s meant to be used. We know it’s meant to be used with that Apple device, and if it shows up somewhere else, we know it’s been compromised and we can kill it.

Meanwhile, Goldman Sachs CEO David Solomon sent a memo to employees this morning celebrating the launch of Apple Card. Solomon explained that while Goldman’s new partnership with Apple is important, “It’s also a beginning.”

Apple Card is Goldman’s first major foray into the consumer banking business through its Marcus division, and Solomon says that he expects the company to be a leader within the next decade.

Apple Card is big, but it’s also a beginning. With no real legacy technology or a longstanding consumer business to defend, we are positioned to innovate, unlike many others in the industry. In the decades to come, I expect us to be a leader in our consumer business, just like we are in our institutional and corporate businesses, with customer-centricity at the core of everything we do.

You can sign up for Apple Card without an invite by going into the Wallet app and tapping the “+” in the upper-right corner. Here’s more about Apple Card:

Jamf

Subscribe to 9to5Mac on YouTube for more Apple news:

Let's block ads! (Why?)


https://9to5mac.com/2019/08/20/apple-card-mastercard-goldman/

2019-08-20 19:05:00Z
52780358612631

U.S. yield curve: Invert, steepen, repeat - Reuters

(Reuters) - A swift steepening of the U.S. 2-year/10-year yield curve after it inverted last week may have given investors hope that the United States can escape recession. They should probably take a breath.

FILE PHOTO: A trader works on the floor at the New York Stock Exchange (NYSE) in New York, U.S., August 9, 2019. REUTERS/Brendan McDermid

History indicates that the reprieve may be brief, before a more sustained, severe flip occurs.

A catalyst for another inversion might happen later this week if the Federal Reserve’s minutes on its July 30-31 meeting on Wednesday or Fed Chairman Jerome Powell’s speech on Friday at the Jackson Hole economic conference were to suggest U.S. policy-makers are not fully on board for an all-out rate-cutting mode, which could drive short-term rates higher and flatten the curve. For an explainer on the yield curve:

The yields on 2-year and 10-year Treasury notes inverted for the first time since 2007 last week, rattling investors who saw this as an omen that a U.S. recession is coming.

While the 2-and-10-year inversion has gone away for now, the previous three bouts of inversion on this part of the yield curve have shown a pattern: a steepen and then return to a more sustained or deeper inversion more than once before a recession hits.

The inversion between three-month Treasury bill rate and 10-year Treasury yield - which economists and some Fed economists believe is a more reliable recession indicator - has been in place since May. That curve inverted in March, steepened in April and then inverted again.

While the stock market reacted with fear after the inversion, there was skepticism from some that a recession would necessarily follow. The yield curve retraced its inversion and stocks rebounded on Monday.

“We would caution against seeing the inversion of the yield curve as an infallible predictor of an economic contraction or a bear market,” UBS Global Wealth Management’s chief investment officer Mark Haefele said.

Currently, some investors said the latest episode of the inversion is overstating the chances of a recession. They argue the Fed’s openness to lower borrowing costs would prolong the current economic expansion, which became the longest on record last month.

“We do not view the inversion of the yield curve as a recessionary signal, and see central banks’ dovish pivot stretching the growth cycle,” said BlackRock Investment Institute on Monday.

Here is how the curve has performed in recent years after an initial inversion:

In February 2006 when the 2-to-10-year part of the curve inverted, that lasted for about a month before 10-year yields rose above their two-year counterparts.

Then the inversion re-emerged about three months later and largely persisted into May 2007.

At the time, the Federal Reserve was at the tail end of a rate-hiking campaign that ultimately raised the federal funds rate to 5.25% in June 2006 from 1.25% in June 2004.

“Although the moderation in the growth of aggregate demand should help to limit inflation pressures over time, the Committee judges that some inflation risks remain,” Fed policy-makers said in a statement after their June 2006 meeting.

Some investors had downplayed the inversion as a harbinger of a looming economic downturn.

In mid-1998, the 2-to-10-year part of the yield curve inverted briefly before a more sustained inversion took place in 2000 while the dotcom stock bubble was imploding which sent the economy into a recession.

From December 1988 to May 1990, the 2-to-10-year part of yield curve inverted on five separate occasions before a recession June 1990.

 In the late 1970s to the early 1980s, curve inversion was a mainstay as then Fed Chairman Paul Volcker sought to combat double-digit inflation by tightening money supply, a move that propelled the federal funds rate above 17% in 1980.

Reporting by Richard Leong; editing by Megan Davies and Lisa Shumaker

Let's block ads! (Why?)


https://www.reuters.com/article/us-usa-economy-yieldcurve/u-s-yield-curve-invert-steepen-repeat-idUSKCN1VA11G

2019-08-20 11:08:00Z
52780356455045

Elanco Announces Agreement to Acquire Bayer's Animal Health Business - Business Wire

GREENFIELD, Ind.--()--Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with Bayer AG (ETR: BAYN) to acquire its animal health business in a transaction valued at US$7.6 billion. The transaction, which is subject to regulatory approval and other customary closing conditions, creates the second largest animal health leader while strengthening and accelerating the company’s proven Innovation, Portfolio and Productivity (IPP) strategy.

The transaction will double Elanco’s Companion Animal business, advancing the company’s intentional portfolio mix transformation and creating a balance between its Food Animal and Companion Animal segments. Elanco expects the combined organization to continue to deliver mid-single digit revenue growth, while accelerating achievement of adjusted gross margin goals and delivering double digit adjusted EBITDA margin growth.

In our first four quarters as an independent company, we have validated the significant value creation potential from a dedicated focus on animal health and a targeted strategy,” said Jeffrey N. Simmons, president and chief executive officer of Elanco. “Joining Elanco and Bayer Animal Health strengthens and accelerates our IPP strategy, transforms our portfolio with the addition of well-known pet brands, brings an increased presence in key emerging markets, expands innovation, and accelerates our margin expansion journey. The move combines our long-standing focus on the veterinarian while meeting pet owners’ changing expectation of pet care and access to products.”

Bayer AG’s chief executive officer, Werner Baumann, added: “Our Animal Health business is among the pioneers of this sector, having built up an attractive portfolio and secured well-established market positions in the companion and farm animal segments. And now, the combination with Elanco will give rise to a leading competitor in the animal health industry, benefiting customers, employees and shareholders alike.”

The addition of Bayer Animal Health enhances all major drivers of Elanco’s IPP strategy.

  • Portfolio: Adding Bayer Animal Health’s business accelerates Elanco’s portfolio transformation by elevating Companion Animal to nearly half of the overall business. The combination creates access to new segments of the parasiticides market with topical treatments and collars, and propels Elanco into expanding pet e-commerce and retail spaces. This complements Elanco’s already strong veterinary presence, enabling the company to reach more pet owners. In the Food Animal business, the acquisition will add a number of anchor cattle brands, create a bio-protection portfolio and expand Elanco’s aqua presence into warm water fish. The enhanced global presence will allow Elanco to better serve veterinarians, farmers and pet owners.
  • Innovation: The transaction augments Elanco’s already strong R&D pipeline with eight significant new development projects and 30+ lifecycle products, while providing certain access rights to Bayer’s CropScience R&D pipeline and de-prioritized clinical pharma assets. It adds superior capabilities for R&D platforms in key areas along with innovative dosing and delivery technology platforms. The acquisition also adds additional bench strength and scale to Elanco’s world-class R&D team.
  • Productivity: The combination of Bayer and Elanco accelerates Elanco’s margin expansion opportunity and delivers adjusted EPS accretion in the first full year post-closing, then high single to low double-digit percentage accretion in year two. The acquisition also unlocks Elanco’s ability to achieve 60 percent adjusted gross margin and 31 percent adjusted EBITDA margin faster than on a stand-alone basis,2 with the increased ability to improve beyond. It brings operating cash flow of approximately $1 billion annually by the third year post-closing, allowing Elanco to reach 3x gross debt to adjusted EBITDA in the same time period, along with the potential for $275 to $300 million in synergies. Finally, Elanco will bring together two complementary dedicated animal health businesses to operate on one fit-for-future infrastructure.

This combination will join two complementary animal health-focused entities previously under the human pharma umbrella into a dedicated company focused on delivering for farmers, veterinarians and pet owners. It creates increased speed, attention and investment to bring customers greater access and options at a variety of price points to make a difference in the lives of animals,” Simmons said. “We look forward to adding Bayer Animal Health’s employees’ breadth of expertise. Ultimately, we believe these increased capabilities and knowledge will allow us to better support the veterinarian, creating a bridge between the pet owner and the veterinarian where relationships don’t exist today.”

Key Terms and Financing
Elanco will finance the transaction through both cash and equity. Bayer AG will receive $5.32 billion in cash, subject to customary purchase price adjustments, and $2.28 billion or approximately 68 million Elanco Animal Health common shares. This represents a 70 percent to 30 percent cash-to-equity mix. Stock received by Bayer is subject to a 7.5 percent symmetrical collar centered on Elanco’s volume-weighted average price for the 30 trading days ended August 6, 2019 of $33.60. Elanco has secured a bridge commitment for the cash portion of the consideration. It intends to fund the cash consideration through a combination of new debt and equity. At close, Elanco expects its gross debt to adjusted EBITDA leverage ratio to be ~5x, including the benefit of expected cost synergies. The strong cash flow generation profile of the combined businesses will allow Elanco to de-lever rapidly to below 3x gross debt to adjusted EBITDA by the end of 2022. The transaction is expected to close in mid-2020, subject to regulatory approvals and other customary closing conditions.

Advisors
Goldman Sachs acted as financial advisor to Elanco and Paul, Weiss, Rifkind, Wharton & Garrison LLP and Hengeler Mueller acted as legal counsel to Elanco. Elanco’s Board of Directors was provided a fairness opinion by Duff & Phelps.

###

WEBCAST AND CONFERENCE CALL DETAILS
Elanco will host a special webcast and conference call at 8:00 a.m. Eastern today, during which company executives will discuss today’s announcements and respond to questions from financial analysts. Investors, analysts, members of the media and the public may access the live webcast and accompanying slides by visiting the Elanco website at https://investor.elanco.com and selecting Events and Presentations. A replay of the webcast will be archived and made available a few hours after the event on the company's website, at https://investor.elanco.com/investor/events-and-presentations.

ABOUT ELANCO
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 65-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life — all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

ABOUT BAYER
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.

Forward Looking Statement

Statements in this release that are not strictly historical, including statements regarding the proposed acquisition of Bayer AG’s animal health business, the expected timetable for completing the transaction, the anticipated financing for the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: (1) the inability to consummate the transaction in a timely manner; (2) the failure of the transaction to close for any other reason; (3) the possibility that the integration of Bayer AG’s animal health business and operations with those of Elanco may be more difficult and/or take longer than anticipated, may be more costly than anticipated and may have unanticipated adverse results relating to Bayer AG’s animal health or Elanco’s existing businesses; (4) the effect of the announcement of the transaction on Elanco’s, Bayer AG’s or the combined company’s respective business relationships, operating results and business generally; (5) diversion of management’s attention from ongoing business concerns; and (6) the ability to obtain or consummate financing or refinancing related to the transaction upon acceptable terms or at all; (7) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction; (8) negative effects of the announcement or the consummation of the transaction on the market price of Elanco’s common stock; (9) the ability of Elanco to retain and hire key personnel; (10) management’s response to any of the aforementioned factors; and (11) other factors that may affect future results of the combined company described in the section entitled “Risk Factors” in Elanco’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and Elanco’s other filings with the Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date hereof and any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.


1 Certain access rights to Bayer CropScience pipeline and de-prioritized pharma clinical assets.

2 2022 vs 2023

Let's block ads! (Why?)


https://www.businesswire.com/news/home/20190820005358/en/Elanco-Announces-Agreement-Acquire-Bayer’s-Animal-Health

2019-08-20 09:30:00Z
52780358671107

Senin, 19 Agustus 2019

Corporate leaders scrap shareholder-first ideology - BBC News

One of the US's most powerful business groups has abandoned the shareholder-first idea that has driven capitalism for decades.

The Business Roundtable said the pursuit of shareholder interests is no longer the central purpose of corporate America.

Companies should focus on social responsibilities as well as profits, the organisation said.

Business Roundtable members include some of the biggest firms in the US.

A statement released on Monday, titled Business Roundtable Redefines the Purpose of a Corporation to Promote "An Economy That Serves All Americans", was signed by the heads of more than 180 US companies. These included the chief executives of Amazon, American Airlines, and America's biggest bank, JPMorgan Chase.

The statement marks the first time the nearly 50-year-old group has said shareholder value is not the first priority. Shareholder primacy was an ethos championed by Nobel Prize-winning economist Milton Friedman and has been the foundation of corporate purpose.

The new mission statement comes at a time when companies are increasingly taking stances on issues outside of the corporate sphere due to pressure from activists amplified by social media and demands from their own employees.

The statement outlines five priorities, including commitments to invest in employees by providing fair wages and "important benefits," support communities where they operate and dealing ethically with suppliers.

'American dream fraying'

"The American dream is alive, but fraying," said Jamie Dimon, chairman and chief executive of JPMorgan Chase, and chairman of Business Roundtable.

"Major employers are investing in their workers and communities because they know it is the only way to be successful over the long term. These modernized principles reflect the business community's unwavering commitment to continue to push for an economy that serves all Americans."

Johnson & Johnson chief executive Alex Gorsky added: "This new statement better reflects the way corporations can and should operate today. It affirms the essential role corporations can play in improving our society when CEOs are truly committed to meeting the needs of all stakeholders."

Other signatories include General Motors' boss Mary Barra, Ford's Jim Hackett, and Apple's Tim Cook.

But some critics were sceptical, with Larry Summers, who served as US Treasury secretary under President Bill Clinton, saying there was no legal requirement on firms to change their approach.

He told the Financial Times: "I worry the Roundtable's rhetorical embrace of stakeholders is in part a strategy for holding off necessary tax and regulatory reform."

Let's block ads! (Why?)


https://www.bbc.com/news/business-49400885

2019-08-19 17:47:33Z
52780357567523

Huawei's 90-day reprieve expires today, so what now? (Update: An extension!) - Android Authority

huawei p30 pro vs huawei mate 20 pro rear side by side 20

Update, August 19 2019 (8:34AM ET): U.S. Commerce Secretary Wilbur Ross has reportedly confirmed that the U.S. has given Huawei a second, 90-day extension.

The Commerce Secretary confirmed the extension with Fox Business Network (h/t: Reuters). This means the Chinese brand is able to keep buying products and services from U.S. companies to service existing customers and devices.

It isn’t all good news for Huawei though, as Ross said 46 more Huawei affiliates will be added to the so-called Entity List. This suggests that it’ll be even tougher for the Chinese manufacturer to do business and to sidestep the trade ban in the future.

Original article, August 19 2019 (1:53AM ET): The U.S. gave Huawei a 90-day reprieve following the trade ban against the manufacturer in May. The trade ban, which allows U.S. companies to maintain business ties with Huawei, expires today (August 19).

Reuters reported on Friday that the U.S. Commerce Department was set to issue another 90-day grace period, citing two sources. The extension would allow Huawei to keep maintaining its current telecommunications networks and updating its Android phones.

Now, the newswire reports that President Donald Trump doesn’t want U.S. firms to deal with the company.

Editor's Pick

“At this moment it looks much more like we’re not going to do business,” Trump told reporters on Sunday before boarding Air Force One, insisting that the firm was a national security threat.

Trump said parts of Huawei’s business could be excluded from a more comprehensive ban, but added that it would be “very complicated.” The president didn’t clarify whether another extension would be granted to the company.

Huawei reassures consumers

Huawei U.K. has also since addressed concerns about the company’s 90-day reprieve elapsing today.

“As we have been saying for some time now, nothing’s changed – and the good thing for our consumers is that nothing will change after August 19. All Huawei smartphones, tablets and PCs which are sold and are selling in the market will continue to receive security patches, Android updates and Microsoft support,” Huawei U.K. explained in an emailed press statement.

The division added that anyone who has bought or is about to buy a Huawei phone can continue to access various apps as they’ve always done, and that devices will still receive full after-sales support.

“Our most popular current devices will be able to access Android Q,” the company continued. It specifically said popular flagship phones such as the Huawei P30 series will “soon” be upgraded to Android Q.

More posts about Huawei

Let's block ads! (Why?)


https://www.androidauthority.com/huawei-90-day-extension-1019197/

2019-08-19 12:54:28Z
52780355407582